Nanotechnology Stocks To Follow Today – March 13th

OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares in companies that research, develop, and commercialize products and processes based on nanoscale materials and technologies. These stocks typically involve firms operating in sectors like electronics, medicine, and energy, where nanotechnology innovations can lead to significant breakthroughs and competitive advantages. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ:OSIS traded down $11.46 during trading hours on Thursday, reaching $170.20. 855,082 shares of the company were exchanged, compared to its average volume of 242,727. The firm has a market cap of $2.86 billion, a PE ratio of 22.00, a price-to-earnings-growth ratio of 1.81 and a beta of 1.20. OSI Systems has a twelve month low of $126.57 and a twelve month high of $220.00. The stock’s 50-day moving average is $188.71 and its 200-day moving average is $166.88. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVEC stock traded down $0.32 during midday trading on Thursday, reaching $64.43. The stock had a trading volume of 9,956 shares, compared to its average volume of 20,615. NVE has a 52-week low of $63.66 and a 52-week high of $90.24. The company has a market cap of $311.65 million, a price-to-earnings ratio of 20.78 and a beta of 1.08. The company’s fifty day simple moving average is $73.85 and its 200 day simple moving average is $76.96.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of NASDAQ BDRX traded up $0.10 during trading on Thursday, hitting $2.06. 113,682 shares of the company were exchanged, compared to its average volume of 351,172. The company’s fifty day moving average is $4.00. Biodexa Pharmaceuticals has a 12-month low of $1.83 and a 12-month high of $74.00.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ CLNN traded down $0.02 on Thursday, reaching $4.38. The stock had a trading volume of 23,661 shares, compared to its average volume of 76,170. Clene has a 12-month low of $3.82 and a 12-month high of $9.76. The firm has a market capitalization of $36.47 million, a price-to-earnings ratio of -0.83 and a beta of 0.27. The stock has a fifty day moving average price of $4.71 and a two-hundred day moving average price of $4.99.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

NASDAQ VRPX traded down $0.00 on Thursday, hitting $0.18. 473,689 shares of the stock were exchanged, compared to its average volume of 6,425,699. Virpax Pharmaceuticals has a fifty-two week low of $0.17 and a fifty-two week high of $4.83. The company has a 50-day moving average price of $0.29 and a 200-day moving average price of $0.49.